Form 4: Domicilium Real Estate Fund III LP SEC Form 4 Filing

Domicilium Real Estate Fund III LP reports an exchange of common stock for pre-funded warrants in Eloxx Pharmaceuticals, Inc.

Summary

• Domicilium Real Estate Fund III LP exchanged 113,636 shares of Eloxx Pharmaceuticals, Inc. common stock for pre-funded warrants.
• The transaction occurred on May 27, 2026.
• The reported figures account for an 11-for-1 reverse stock split that became effective on May 29, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting a change in the form of equity held by a major shareholder rather than a fundamental shift in company outlook.

Positives

• The exchange of common stock for pre-funded warrants provides the holder with flexibility regarding the timing of equity acquisition.

Negatives

• The reporting entity has reduced its direct holdings of common stock through this exchange.

Risks

• Pre-funded warrant exercise is subject to a 4.99% beneficial ownership limitation, which may restrict the holder's ability to increase their stake rapidly.
• The issuer is subject to market volatility and the inherent risks associated with pharmaceutical development.

Future Outlook

The filing does not provide forward-looking guidance regarding the company's business operations, focusing solely on the change in beneficial ownership.

Industry Context

StockSavvy.ai notes that institutional investors often utilize pre-funded warrants in biotech to manage ownership thresholds and regulatory reporting requirements while maintaining economic exposure to the issuer.

Comparison to Industry Standards

• The use of pre-funded warrants is a standard mechanism in the biotechnology sector to navigate ownership caps and facilitate capital structure adjustments.
• The 4.99% ownership limitation is a common provision in institutional investment agreements to avoid triggering change-of-control or regulatory filing complexities.

Related Party Transactions

• The filing discloses that the securities are beneficially owned by Domicilium Capital Partners LLC and Daniel Simon, who serve as investment adviser and managing member, respectively.

Stakeholder Impact

• Shareholders should note the change in the form of ownership held by a 10% owner, though the total economic interest remains largely unchanged.

Next Steps

• The reporting person may exercise the pre-funded warrants at their discretion, subject to the 4.99% ownership cap.

Key Dates

Keywords

Eloxx Pharmaceuticals, ELOX, Form 4, Insider Trading, Pre-funded Warrants, Beneficial Ownership